Is Royalty Pharma (RPRX) Still Attractive After A 35% One Year Share Price Gain [Yahoo! Finance]
Royalty Pharma plc - Class A Ordinary Shares (RPRX)
US:NASDAQ Investor Relations:
ir.reprosrx.com/investor-relations
Company Research
Source: Yahoo! Finance
If you are wondering whether Royalty Pharma's current share price still offers value, looking at how the market has been treating the stock recently is a useful starting point. The shares last closed at US$41.68, with returns of 3.2% over the past week, 7.3% over the past month, and 35.3% over the past year, which has caught the attention of investors watching for shifts in sentiment and risk. Recent news flow around Royalty Pharma has focused on its role in funding biopharmaceutical royalties and its position within the broader healthcare and biotech ecosystem. This often shapes how investors think about the durability of its cash flows and deal pipeline. This context helps frame why the share price performance over the last year has been closely watched, especially by investors comparing it to other specialist royalty or healthcare names. On our valuation checks, Royalty Pharma scores 3 out of 6 for being potentially undervalued. Next, we look at what different valuation meth
Show less
Read more
Impact Snapshot
Event Time:
RPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPRX alerts
High impacting Royalty Pharma plc - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
RPRX
News
- Royalty Pharma (NASDAQ:RPRX) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating.MarketBeat
- Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma (NASDAQ:RPRX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- Jim Cramer on Royalty Pharma: “It's a Terrific Company” [Yahoo! Finance]Yahoo! Finance
- Lightning Round: Coherent is a winner, says Jim Cramer [CNBC]CNBC
RPRX
Sec Filings
- 2/2/26 - Form 144
- 2/2/26 - Form 4
- 1/26/26 - Form 4
- RPRX's page on the SEC website